Pasithea Therapeutics Corp. (KTTA): Nasdaq/NYSE listing notice — Pasithea Therapeutics receives Nasdaq deficiency notice for minimum bid price non-compliance

Pasithea Therapeutics Corp.

Received Nasdaq notice on Jan 19, 2023 for failure to meet $1.00 minimum bid price rule (Nasdaq 5550(a)(2)).
Company has 180 calendar days, until July 18, 2023, to regain compliance; stock must close at $1.00+ for 10 consecutive days.
If not cured, may request additional 180 days if meeting other listing requirements and intending reverse stock split.
Failure to regain compliance could lead to delisting; company is considering options to cure deficiency.
Receipt of notice does not affect business operations or SEC reporting requirements.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 19, 2023, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pri

View on SEC.gov

16 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Pasithea Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001213900-23-004881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.